Replies to post #305735 on Avid Bioservices Inc (CDMO)

[Threes]

Again CP time and money, You point out two trials needed a positive it works and a negative without ineffective.
Once you have that in mIce apply to the FDA. start the ten to twelve year journey get through Phase 3 and apply NDA.

What resources do we have and where will the additional resources come from.
What is the back up plan should unforeseen negative results are achieved.

I am still holding out for your prediction of time and money. How many OS will be issued. What will the dilution be. Will we need more then one additional RS to get there?

Seems I am on 15 post day limit that seems new.
Wonder why , actually still wonder why a post liked by some here was deleted.

[goodJohnhunting]

With Bavituximab or BetaBodies one circumvents all that and simply bind PdSer (the LIGAND alike concept in PS world that binds PS-R the PS receptors).

BetaBodies don't rely on binding domains (b2gp1). However, would this circumventing create a paradox for attachment?

It appears obvious that eliminating binding traffic is paramount to success. In theory, statins would be synergistic in this regard, I/O combo's not so much, IMO.

I'm confident that this will eventually be tested. In the least, something similar to statin.

All the best,
John

[vinmantoo]

vinmantoo, CP is not wrong :)

Actually, everything you just you wrote (copied) proves I am right. Thanks. PS is not just present on tumor cells but gets exposed on apoptotic cells throughout the body. That extra PS acts as a sink to draw away anti-PS antibodies. It couldn't be more clearer than that.

Quote:it explains why Bavi likely isn't a good anti-cancer target



But hey, I give you the word LIKELY. And by the way I we need a clinical trial to prove Bavi works with IO then you need one to prove it doesn't work with IO. And since there isn't any public data...at my knowledge.

As a scientist, I try not to use absolutes even in cases where data suggests little chance for success, like in the case of Bavi so I used "likely ins't a good target". More importantly, there is no data from ANY clinical trials showing Bavi it has any efficacy as a single agent. That is a major strike against it.